These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7999989)

  • 1. Effect of purified IgGs from HIV-1-infected and non infected individuals on immune activation.
    Chams V; Biou D; Cho YY; Mbika JP; Le Coq H; Heshmati F; Fouchard M; Bizzini B; Zagury JF
    Biomed Pharmacother; 1994; 48(5-6):267-72. PubMed ID: 7999989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striking similarities between HIV-1 Env protein and the apoptosis mediating cell surface antigen Fas. Role in the pathogenesis of AIDS.
    Zagury JF; Cantalloube H; Achour A; Cho YY; Fall L; Lachgar A; Chams V; Astgen A; Biou D; Picard O
    Biomed Pharmacother; 1993; 47(8):331-5. PubMed ID: 7520296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-gamma restores HIV- and non-HIV-specific cell mediated immune response in vitro and its activity is neutralized by antibodies from patients with AIDS.
    De Francesco MA; Caruso A; Dima F; Cantalamessa A; Canaris AD; Folghera S; Fiorentini S; Flamminio G; Licenziati S; Peroni L; Gao J; Garotta G; Turano A
    Scand J Immunol; 1996 Jan; 43(1):94-100. PubMed ID: 8560203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesis.
    Zagury JF; Bernard J; Achour A; Astgen A; Lachgar A; Fall L; Carelli C; Issing W; Mbika JP; Picard O
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7573-7. PubMed ID: 8356059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
    Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV type 1 envelope glycoprotein 120 carboxy-terminal peptide-induced human T cell lines selectively suppress heterogeneous proliferative T cell responses to soluble antigens.
    Wilson SE; Habeshaw JA; Addawe MA; Hounsell EF; Oxford JS
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1313-24. PubMed ID: 9339848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection.
    Beretta A; Furci L; Burastero S; Cosma A; Dinelli ME; Lopalco L; DeSantis C; Tambussi G; Carrow E; Sabbatani S; Clerici M; Lazzarin A; Siccardi AG
    Immunol Lett; 1996 Jun; 51(1-2):39-43. PubMed ID: 8811343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals.
    Kozlowski PA; Chen D; Eldridge JH; Jackson S
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):813-22. PubMed ID: 7986587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of IgA inhibiting the interaction between gp120 and soluble CD4 receptor in serum and saliva of HIV-1-infected patients.
    Vincent N; Malvoisin E; Pozzetto B; Lucht F; Genin C
    AIDS; 2004 Jan; 18(1):37-43. PubMed ID: 15090827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1-induced immune suppression may result from autoimmune disorders including anti-SLWDQ autoantibodies.
    Zagury JF; Bernard J; Achour A; Astgen A; Lachgar A; Fall L; Carelli C; Issing W; Mbika JP; Cantalloube H
    Biomed Pharmacother; 1993; 47(2-3):93-9. PubMed ID: 8218954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of an eight amino acid domain shared by Fas (CD95/Apo-I) and HIV-1 gp120. I. Structural and antigenic analysis.
    Silvestris F; Cocco T; Cafforio P; Calvani N; Dammacco F
    Mol Med; 2000 Jun; 6(6):494-508. PubMed ID: 10972086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic implication of specific immunoglobulin G patterns of children born to HIV-infected mothers.
    Broliden PA; Moschese V; Ljunggren K; Rosen J; Fundaro C; Plebani A; Jondal M; Rossi P; Wahren B
    AIDS; 1989 Sep; 3(9):577-82. PubMed ID: 2551341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological properties of anti-CD4 autoantibodies purified from HIV-infected patients.
    Chams V; Idziorek T; Klatzmann D
    AIDS; 1991 May; 5(5):565-9. PubMed ID: 1677809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
    Wrin T; Nunberg JH
    AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602
    [No Abstract]   [Full Text] [Related]  

  • 15. Alternative complement pathway activation by CD4+ T cells of HIV infected individuals: a possible role in AIDS pathogenesis.
    Yefenof E; Magyarlaki T; Fenyo EM; Wahren B; Klein E
    Int Immunol; 1994 Sep; 6(9):1361-6. PubMed ID: 7819144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of complement and gp120-specific antibodies in virus lysis and CD4+ T cell depletion in HIV-1-infected patients.
    Gerencer M; Burek V; Crowe BA; Barrett NP; Dorner F
    Microb Pathog; 1998 Nov; 25(5):253-66. PubMed ID: 9878454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition.
    Vahlne A; Horal P; Eriksson K; Jeansson S; Rymo L; Hedström KG; Czerkinsky C; Holmgren J; Svennerholm B
    Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10744-8. PubMed ID: 1961741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idiotypic expression of anti-gp120 antibodies in unrelated human immunodeficiency virus-infected individuals.
    Février M; Boudet F; Corre JP; Chamaret S; Thèze J; Zouali M
    J Gen Virol; 1992 Oct; 73 ( Pt 10)():2561-8. PubMed ID: 1383396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
    Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
    Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.